Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, South Korea.
Hepatol Int. 2019 Mar;13(2):205-213. doi: 10.1007/s12072-018-09926-z. Epub 2019 Jan 29.
Advanced fibrosis associated with nonalcoholic fatty liver disease (NAFLD) has been reported to have a higher risk of hepatic and non-hepatic mortality. We aim to study the recent trends in the prevalence of NAFLD-related advanced fibrosis in a large population sample.
Cross-sectional data from 28,739 participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2016 were utilized. NAFLD was defined using the hepatic steatosis index (HSI) and the US fatty liver index (USFLI) in the absence of other causes of chronic liver disease. The presence and absence of advanced fibrosis in NAFLD was determined by the NAFLD fibrosis score, FIB-4 score, and aspartate aminotransferase-to-platelet ratio index.
The prevalence of NAFLD-related advanced fibrosis increased from 2.6% [95% confidence interval (CI) 2.1-3.1] in 2005-2008 and 4.4% (95% CI 3.7-5.1) in 2009-2012, to 5.0% (95% CI 4.2-5.9) in 2013-2016 using HSI as the NAFLD prediction model; and from 3.3% (95% CI 2.5-4.5) in 2005-2008 and 6.4% (95% CI 3.7-5.1) in 2009-2012, to 6.8% (95% 5.3-8.7) in 2013-2016 using USFLI (p < 0.01). A similar trend was observed in entire NHANES cohort regardless of NAFLD status. While the prevalence of advanced fibrosis increased steadily in non-Hispanic whites through the duration of the study, it leveled off during 2013-2016 in non-Hispanic blacks.
Prevalence of advanced fibrosis associated with NAFLD increased steadily from 2005 to 2016. More importantly, race/ethnicity-based temporal differences were noted in the prevalence of NAFLD-related advanced fibrosis during the study.
非酒精性脂肪性肝病(NAFLD)相关的晚期纤维化已被报道具有更高的肝性和非肝性死亡率。本研究旨在研究大样本人群中 NAFLD 相关晚期纤维化的流行趋势。
利用 2005 年至 2016 年 28739 名参与国家健康和营养调查(NHANES)的横断面数据。NAFLD 采用肝脂肪指数(HSI)和美国脂肪肝指数(USFLI)定义,无其他慢性肝病病因。NAFLD 纤维化的有无通过 NAFLD 纤维化评分、FIB-4 评分和天冬氨酸氨基转移酶与血小板比值指数来确定。
采用 HSI 作为 NAFLD 预测模型,NAFLD 相关晚期纤维化的患病率从 2005-2008 年的 2.6%(95%CI 2.1-3.1)和 2009-2012 年的 4.4%(95%CI 3.7-5.1)增加至 2013-2016 年的 5.0%(95%CI 4.2-5.9);采用 USFLI,患病率从 2005-2008 年的 3.3%(95%CI 2.5-4.5)和 2009-2012 年的 6.4%(95%CI 3.7-5.1)增加至 2013-2016 年的 6.8%(95%CI 5.3-8.7)(p<0.01)。在整个 NHANES 队列中,无论是否存在 NAFLD,均观察到类似的趋势。在研究期间,非西班牙裔白种人的晚期纤维化患病率稳步上升,但在 2013-2016 年期间,非西班牙裔黑种人的患病率趋于平稳。
2005 年至 2016 年,NAFLD 相关晚期纤维化的患病率稳步上升。更重要的是,在研究期间,基于种族/民族的 NAFLD 相关晚期纤维化的流行存在时间差异。